Scholars@Duke
Michael John Kelley

Michael John Kelley

Professor of Medicine
Medicine, Medical Oncology
michael.kelley@duke.edu
Duke Box 3396, Durham, NC 27710
508 Fulton St; Hem-Onc 111G, Durham, NC 27705

Scholarly Works - Conferences

Real-world outcomes associated with tarlatamab for extensive-stage small cell lung cancer (ES-SCLC) in the Veterans Health Administration (VA).

Conference Journal of Clinical Oncology · June 1, 2026 e20153Background: ES-SCLC remains an aggressive malignancy with a very poor prognosis ... Full text Cite

Homologous recombination repair (HRR) genes and overall survival prognosis within the STRATOS-P classification in metastatic hormone-sensitive prostate cancer (mHSPC).

Conference Journal of Clinical Oncology · June 1, 2026 5108Background: DNA repair genomic alterations are associated with worse overall surv ... Full text Cite

Abstract 7267: Genomic architecture of prostate cancer in BRCA1/2 germline carriers

Conference Cancer Research · April 3, 2026 AbstractBackground:Inherited pathogenic germline variants (PGVs) in BRCA1 and BRCA2 are significant risk factors for the develo ... Full text Cite

Enabling national identification of lung cancer screening eligibility with large language models.

Conference Journal of Clinical Oncology · June 2025 e13613Background: Lung cancer (LC) is the leading cause of cancer-related death, yet screening uptake among eligible individu ... Full text Cite

CemiplimAb-rwlc survivorship and epidemiology (CASE): Interim results from a prospective study of the safety and effectiveness of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC) in a real-world setting.

Conference Journal of Clinical Oncology · June 2025 9533Background: Cemiplimab is the first PD-L1 inhibitor approved for the treatment of patients with locally advanced (la) or ... Full text Cite

Real world efficacy and safety of ivosidenib in US veterans with IDH1 mutated cholangiocarcinoma.

Conference Journal of Clinical Oncology · June 2025 4086Background: IDH1 mutations occur in 13% of patients with intrahepatic cholangiocarcinoma. Ivosidenib is FDA approved for ... Full text Cite

Social vulnerability by neighborhood of association correlates with CAR T referrals.

Conference Journal of Clinical Oncology · June 2025 7025Background: Chimeric antigen receptor T (CAR T) cell therapies are effective for relapsed/refractory (R/R) diffuse large ... Full text Cite

Outcomes of germline expedited point of care (POC) genetic testing through telehealth in the Veterans Health Administration (VA)

Conference Journal of Clinical Oncology · January 1, 2025 Background: Germline genetic testing is standard of care for treatment planning for several malignancies. To increase access to genetic testing for Veterans, VA developed and disseminated educational materials, laboratory portal access, and templates for o ... Full text Cite

Oncogenic alteration rates, race, and prostate cancer specific mortality in Veterans with metastatic prostate cancer undergoing somatic tumor next generation sequencing.

Conference Journal of Clinical Oncology · June 1, 2024 5017Background: National guidelines recommend next generation sequencing (NGS) of tumors from patients diagnosed with metastatic prostate cancer (PCa) to identify potential actionable alterations. We sought to determine associations between alteration freq ... Full text Cite

Quality of telehealth-provided cancer care in VA

Conference JOURNAL OF CLINICAL ONCOLOGY · June 1, 2024 Link to item Cite

Researcher Experience and Comfort With Telemedicine and Remote Patient Monitoring in Cancer Treatment Trials.

Conference Oncologist · April 4, 2024 BACKGROUND: Since the onset of COVID-19, oncology practices across the US have integrated telemedicine (TM) and remote patient monitoring (RPM) into routine care and clinical trials. The extent of provider experience and comfort with TM/RPM in treatment tr ... Full text Link to item Cite

Abstract 919: Veterans Health Administration: Decentralized clinical trials

Conference Cancer Research · March 22, 2024 AbstractPurpose: The Veterans Health Administration (VA) created National TeleOncology (NTO) service in 2019 to provide telehealth cancer care to Veterans and to augment care provided at VA facilities throug ... Full text Cite

Impact of Social Determinants of Health and Novel Therapies on the Outcomes of Relapsed and Refractory Diffuse Large B Cell Lymphoma

Conference Blood · November 2, 2023 Introduction:Outcomes for patients with relapsed and refractory diffuse large B cell lymphoma (R/R DLBCL) have improved dramatically with the recent approvals of chimeric antigen recepto ... Full text Cite

Tolerability and Outcomes of Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia in Patients with Severe Renal Dysfunction

Conference Blood · November 2, 2023 Introduction:There is limited data on the outcomes and tolerability of Bruton Tyrosine Kinase (BTK) inhibitors for chronic lymphocytic leukemia (CLL) in patients with severe renal dysfun ... Full text Cite

Success of Liquid Tumor Biopsy in Men with Metastatic Prostate Cancer According to Self-Identified Race

Conference INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS · October 1, 2023 Link to item Cite

Telemedicine-supervised cancer therapy for patients with an aggressive lymphoma and metastatic lung cancer in the U.S. Veterans Affairs National TeleOncology Service.

Conference Journal of Clinical Oncology · June 1, 2023 1602 Background: Telemedicine is increasingly used in cancer care but has mostly been applied to surveillance and oral therapy rather than parenteral treatments. In the U.S. Veterans Affairs National TeleOncology service (NTO), p ... Full text Cite

Real-world rates of FDA-approved targeted therapy and immunotherapy prescriptions for patients with metastatic colorectal cancer in the VA’s National Precision Oncology Program (NPOP).

Conference Journal of Clinical Oncology · June 1, 2023 3602 Background: Colorectal cancer is the fourth most common cancer among Veterans and the third leading cause of cancer-related death in the USA. Use of comprehensive genomic profiling (CGP) to guide administration of FDA-approv ... Full text Cite

Expanding veteran treatment access points through Close To Me (CTM) infusion service.

Conference Journal of Clinical Oncology · June 1, 2023 1519 Background: Diagnosing and treating more than 43,000 Veterans annually, the Veterans Affairs (VA) National Oncology Program (NOP) oversees the largest integrated providers of hematology/oncology services in the US. Within th ... Full text Cite

Clinical factors associated with successful liquid tumor biopsy in men with prostate cancer.

Conference Journal of Clinical Oncology · June 1, 2023 e13567 Background: Liquid biopsies using cell-free DNA (cfDNA) can be used in prostate cancer (PrCa) patients when tissue is unavailable and repeat biopsy is not feasible. Given the older age of PrCa patients, liquid biopsy may d ... Full text Cite

Genomic alterations and self-reported Agent Orange exposure in United States veterans with metastatic prostate cancer.

Conference Journal of Clinical Oncology · June 1, 2023 5068 Background: Agent Orange has been posited as an environmental risk factor for prostate cancer among United States Veterans. Prior studies have shown that Veterans with Agent Orange exposure are diagnosed at a younger age and ... Full text Cite

Metastatic bulk to predict subclonal heterogeneity by ctDNA in RAS/RAF-wildtype colorectal cancer.

Conference Journal of Clinical Oncology · February 1, 2022 186 Background: Distinct molecular subgroups of colorectal cancer (CRC) have been afforded with use of next-generation sequencing (NGS) as standard in clinical practice for advanced disease. We have previously demonstrated that d ... Full text Cite

Recommendation on Advanced Molecular Testing in Hematolymphoid Malignancies in the Veterans Population

Conference Blood · November 5, 2021 AbstractThe Veterans Health Administration is the largest integrated provider of cancer services in the nation, with approximately 50,000 new cancer cases diagnosed each year. The goal of the VA's National O ... Full text Cite

Barriers to Prescribing Targeted Therapies for Patients With NSCLC With Highly Actionable Gene Variants in the Veterans Affairs National Precision Oncology Program.

Conference JCO Oncol Pract · July 2021 PURPOSE: Next-generation sequencing (NGS) gene panels are frequently completed for patients with advanced non-small-cell lung cancer (NSCLC). Patients with highly actionable gene variants have improved outcomes and reduced toxicities with the use of corres ... Full text Link to item Cite

Real-world outcomes among prostate cancer patients with BRCA2 gene variants compared to variants in other homologous DNA repair genes.

Conference Journal of Clinical Oncology · May 20, 2021 e17033 Background: PARP inhibitors (PARPis) were approved by the FDA for the treatment of advanced prostate cancer (PC) among patients (pts) harboring mutations in genes responsible for homologous DNA repair. Increasing evidence ... Full text Cite

Cancer specialists in the VA as early adopters of clinical genetic services.

Conference Journal of Clinical Oncology · May 20, 2021 11029 Background: Genetic testing has become essential to delivery of cancer treatment, risk assessment, surveillance, and prevention. We sought to understand the use of genetic tests by clinicians in the Department of Veterans A ... Full text Cite

Suicide risk following a new cancer diagnosis among veterans in Veterans Health Administration care.

Conference Journal of Clinical Oncology · May 20, 2021 12130 Background: Patients diagnosed with cancer are at an increased risk of adverse mental health outcomes including suicidal behavior. Suicide rates among Veterans are 50 percent greater than for non-Veteran US adults. To infor ... Full text Cite

TARGETING SMARCBi IN PEDIATRIC CHORDOMA DEVELOPMENT

Conference ONCOLOGY NURSING FORUM · March 2021 Link to item Cite

Abstract PR11: Racial differences in characteristics of early- vs. late-onset colorectal cancer among veterans

Conference Cancer Epidemiology, Biomarkers & Prevention · June 1, 2020 AbstractIntroduction: Colorectal cancer (CRC) accounts for approximately 8% of annual cancer cases in the Veterans Health Administration. While CRC incidence is decreasing, evidence suggests that the inciden ... Full text Cite

An NLP tool to identify molecular diagnostic testing in veterans with stage IV NSCLC.

Conference Journal of Clinical Oncology · September 20, 2019 318 Background: ASCO Quality Oncology Practice Initiative (QOPI) encourages hospitals to determine if patients (pts) with stage IV NSCLC adenocarcinoma have activating EGFR mutations. Guidelines recommend tumor testing to identif ... Full text Cite

Genomic analysis of metastatic solid tumors in veterans: Findings from the VHA National Precision Oncology Program.

Conference Journal of Clinical Oncology · May 20, 2019 3074Background: Scalable next generation sequencing (NGS) technologies have enabled incorporation of precision oncology into ... Full text Cite

Implementation of the VA Symptom Assessment Scale (VSAS): Five-year experience.

Conference Journal of Clinical Oncology · May 20, 2019 e23120 Background: Cancer patients experience symptoms which may precede diagnosis, occur during therapy, and persist into survivorship. Symptom assessments and patient reported outcomes have been shown to improve quality of life ... Full text Cite

The Veterans Health Administration Precision Oncology Program for Advanced Prostate Cancer Patients: Expanding tumor NGS opportunities to a broader patient population.

Conference Journal of Clinical Oncology · March 1, 2019 193 Background: Progress in understanding molecular changes in advanced prostate cancer has led to promising precision oncology opportunities; to date, most have been concentrated at tertiary research centers and urban centers an ... Full text Cite

Modeling and Prediction of SIB Prostate IMRT Plans

Conference International Journal of Radiation Oncology*Biology*Physics · November 2018 Full text Cite

National trends in end of life care for veterans with advanced cancer.

Conference Journal of Clinical Oncology · October 20, 2018 3 Background: It is imperative to provide quality end of life (EOL) care for cancer patients. This entails minimizing aggressive measures at the EOL. Although rates of hospice utilization within the Veteran’s Health Administratio ... Full text Cite

Cardiovascular disease-related chronic conditions among Veterans Affairs colorectal cancer survivors: A matched case-control analysis.

Conference Journal of Clinical Oncology · March 1, 2018 4 Background: The growing number of colorectal cancer (CRC) survivors often have multiple chronic conditions. Comparing CRC survivors and matched non-cancer controls, our objectives were to determine the odds of CRC survivors bei ... Full text Cite

Role of adjuvant chemotherapy following chemoradiation and surgery for locoregionally advanced rectal cancer: A Veterans Health Administration analysis.

Conference Journal of Clinical Oncology · February 1, 2018 741 Background: Adjuvant chemotherapy (AC) following chemoradiation (CRT) and total mesorectal excision (TME) for locoregionally advanced rectal cancer (LARC) is a standard of care in the United States despite limited data. The p ... Full text Cite

Once Versus Twice Daily Fractionation for Limited Stage SCLC

Conference International Journal of Radiation Oncology*Biology*Physics · October 2017 Full text Cite

Non-operative Management for Locally Advanced Rectal Cancer in the Veterans Health Administration

Conference International Journal of Radiation Oncology*Biology*Physics · October 2017 Full text Cite

Short- and long-term outcomes of early stage non-small cell lung cancer (NSCLC) surgery.

Conference Journal of Clinical Oncology · May 20, 2017 8544 Background: The goal of this study was to determine patient factors associated with short- vs long-term survival after surgery for stage I/II NSCLC and assess the distribution of causes of death over time. Methods: Using the ... Full text Cite

Abstract 2037: A discovery study to identify clinical and genetic risk factors for bevacizumab (BEV)-related gastrointestinal (GI) hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated on CALGB 90401 (Alliance)

Conference Cancer Research · July 15, 2016 AbstractBackground: Treatment-related GI HEM is a major health concern with few known predictive risk factors. The objective of this analysis was to discover clinical and genetic factors that modulate GI HEM ... Full text Cite

Colorectal cancer survivorship statistics: A Veterans Affairs Central Cancer Registry analysis.

Conference Journal of Clinical Oncology · January 20, 2016 e267 Background: Our objective was to evaluate VA CRC incidence and survival and compare with the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) data. Methods: Data were obtained from VACCR for vet ... Full text Cite

Utilization of BRCA1/BRCA2 testing in Veterans Health Administration.

Conference Journal of Clinical Oncology · May 20, 2015 Full text Cite

Nonmuscle myosin II-A plays a role in sperm development.

Conference MOLECULAR BIOLOGY OF THE CELL · January 1, 2015 Link to item Cite

Adjuvant Chemotherapy for Older Patients With Early-Stage Non-Small Cell Lung Cancer

Conference International Journal of Radiation Oncology*Biology*Physics · November 2014 Full text Cite

Tools to accurately identify veterans who undergo molecular diagnostic testing.

Conference Journal of Clinical Oncology · November 1, 2013 201 Background: Yearly, 52,000 veterans are diagnosed with cancer. Minorities represent 18.5% (9,651) of these patients. The rapid and explosive growth of molecular diagnostics (MDx) has created challenges for large healthcare sy ... Full text Cite

Abstract 352: Murine model of chordoma: Sonic Hedgehog promoter-driven Cre activation of Brachyury (T) expression induces spinal disk abnormalities and perinatal lethal developmental defects.

Conference Cancer Research · April 15, 2013 AbstractIntroduction: Chordoma is a rare malignancy arising in the axial skeleton from notochord remnants. The T-box transcription factor, Brachyury (T), is associated with familial chordoma, is expressed in ... Full text Cite

Generating laminar, reproducible flow rates by modeling transport properties of the hydrofluoric acid-sulfuric acid mixture

Conference Process Development Division Core Programming Topic at the 2011 Aiche Annual Meeting · January 1, 2011 The Thomas Jefferson National Accelerator Facility (Jefferson Lab) aims to maximize the performance of particle accelerators by perfecting superconducting radiofrequency (SRF) technology. Smooth niobium interior cavities ensure that electron beams do not s ... Cite

A genomic strategy to combinatorial therapeutics in solid tumors.

Conference JOURNAL OF CLINICAL ONCOLOGY · June 20, 2006 Link to item Cite

Genetic heterogeneity in familial chordoma

Conference AMERICAN JOURNAL OF HUMAN GENETICS · November 1, 2003 Link to item Cite

Randomized controlled clinical trial of weekly oltipraz in smokers.

Conference CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION · October 1, 2002 Link to item Cite

Genomic screen for linkage in a family with autosomal dominant chordoma.

Conference AMERICAN JOURNAL OF HUMAN GENETICS · October 1997 Link to item Cite